南昌治疗抑郁大概多少钱啊(南昌那个医院治疗发狂好点) (今日更新中)

BEIJING, Feb. 20 (Xinhua) -- China's railways handled 7.13 million passengers Saturday, setting a new one day record, the Ministry of Railways (MOR) said Sunday.The figure was 16 percent higher year on year, the MOR said.Chinese railways are witnessing a new wave of travel after the Lantern Festival celebration (the 15th day of the first month in the Lunar New Year) Thursday, which is considered a symbolic ending of the festival season.China's Spring Festival fell on Feb. 3 this year.The busy Spring Festival transportation season runs for 40 days and is calculated in two phases: 15 days before the Spring Festival and 25 days after the Spring Festival.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

CANBERRA, May 27 (Xinhua) -- An Australian student has discovered a part of the universe that astrophysicists have spent decades trying to find, Australia's Monash University on Friday confirmed in a statement.Astrophysicists have long thought the universe has a greater mass than is visible in the planets, but they had no way of proving it is there.Undergraduate student Amelia Fraser-McKelvie, 22, was on a summer internship at Monash University to learn more about astrophysics, when she managed to solve one of the big mysteries of science.Fraser-McKelvie, an aerospace engineering student, conducted a targeted X-ray search for the matter and found evidence of it within three months.Her tutor, Kevin Pimbblet, said the discovery is significant."We've been looking for this ordinary matter for a couple of decades," he said in a statement on Friday."It's been published in one of the most prestigious journals in the world, so astronomers all over the world will be able to read this article."Scientists had thought the matter would have a temperature of about 1 million degrees Celsius, 1.8 million degrees Fahrenheit, and should therefore be observable at X-ray wavelengths.Amelia Fraser-McKelvie's discovery has proved that prediction is correct, Pimbblet said.The trio published a research paper on the missing mass in one of the world's oldest and most prestigious scientific journals, Monthly Notices of the Royal Astronomical Society.He said the discovery could change the way telescopes are built.

BEIJING, Apirl 1 (Xinhuanet) -- An Ariane rocket launch of two communications satellites was aborted Wednesday after a technical hitch at the scheduled moment of liftoff in French Guiana on Wednesday.According to Arianespace, the Ariane 5 rocket's Vulcain main engine ignited as scheduled at 5:45 pm EDT (21:45 GMT), but the checkout process during ignition detected an unspecified anomaly, shutting down the engine before the two solid-rocket boosters ignited.The 165-foot (50-meter) tall Ariane 5 rocket's main engine's checkout process "was not completed successfully, preventing the boosters' ignition and thereby aborting the mission," Arianespace officials said. "The Ariane 5 and its two payloads remain in a safe mode on the launch pad."The Ariane 5 rocket uses a Vulcain 2 first stage engine assisted by two solid rocket boosters to launch satellite payloads into orbit. The Vulcain 2 engine is fueled by cryogenic liquid hydrogen and liquid oxygen and is designed to burn for about 600 seconds to boost payloads into space.Jean-Yves Le Gall, Arianespace president, said it would return the rocket to the final assembly building to prepare it for another launch attempt while investigating the cause of the problem. No new launch date was immediately announced.The Ariane 5 was to launch the Yahsat Y1A and Intelsat New Dawn communications satellites.

来源：资阳报